EP1189624A4 - Hla-bindende peptide und deren verwendung - Google Patents
Hla-bindende peptide und deren verwendungInfo
- Publication number
- EP1189624A4 EP1189624A4 EP00944976A EP00944976A EP1189624A4 EP 1189624 A4 EP1189624 A4 EP 1189624A4 EP 00944976 A EP00944976 A EP 00944976A EP 00944976 A EP00944976 A EP 00944976A EP 1189624 A4 EP1189624 A4 EP 1189624A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- binding peptides
- peptides
- hla binding
- immunogenic
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108700028369 Alleles Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07117445A EP1917970B1 (de) | 1999-06-29 | 2000-06-28 | Hla-bindende Peptide und ihre Verwendungen |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14142299P | 1999-06-29 | 1999-06-29 | |
US141422P | 1999-06-29 | ||
PCT/US2000/017842 WO2001000225A1 (en) | 1999-06-29 | 2000-06-28 | Hla binding peptides and their uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07117445A Division EP1917970B1 (de) | 1999-06-29 | 2000-06-28 | Hla-bindende Peptide und ihre Verwendungen |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1189624A1 EP1189624A1 (de) | 2002-03-27 |
EP1189624A4 true EP1189624A4 (de) | 2005-02-23 |
Family
ID=22495620
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00944976A Withdrawn EP1189624A4 (de) | 1999-06-29 | 2000-06-28 | Hla-bindende peptide und deren verwendung |
EP07117445A Expired - Lifetime EP1917970B1 (de) | 1999-06-29 | 2000-06-28 | Hla-bindende Peptide und ihre Verwendungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07117445A Expired - Lifetime EP1917970B1 (de) | 1999-06-29 | 2000-06-28 | Hla-bindende Peptide und ihre Verwendungen |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1189624A4 (de) |
JP (1) | JP2003535024A (de) |
AT (1) | ATE512666T1 (de) |
AU (1) | AU5898400A (de) |
CA (1) | CA2370413A1 (de) |
WO (1) | WO2001000225A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US20040096445A1 (en) * | 1999-06-30 | 2004-05-20 | John Sidney | Subunit vaccines with A2 supermotifs |
US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
WO2001021189A1 (en) * | 1999-07-19 | 2001-03-29 | Epimmune Inc. | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
DK1230268T3 (da) | 1999-11-18 | 2010-02-08 | Epimmune Inc | Heteroklitiske analoger af klasse I-epitoper |
US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
CA2393738A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
WO2001074847A2 (en) * | 2000-03-30 | 2001-10-11 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer |
EP1292321B1 (de) * | 2000-05-12 | 2011-10-26 | NorthWest Biotherapeutics, Inc. | Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen |
EP3184539A3 (de) | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antikörper |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
GB0203419D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
GB0203420D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
US20080274129A1 (en) * | 2003-04-18 | 2008-11-06 | Fikes John D | Hla-A2 Tumor Associated Antigen Peptides and Compositions |
TWI262192B (en) * | 2003-07-01 | 2006-09-21 | Univ Nat Taiwan | Labeling peptide for nasopharyngeal carcinoma (NPC) cells |
GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
JP2007277092A (ja) * | 2004-06-17 | 2007-10-25 | Univ Kurume | 前立腺関連抗原由来hla−a2結合性ペプチド |
EP1840133A1 (de) * | 2006-03-29 | 2007-10-03 | Global Biotech Development Corp. Ltd. | Neue immunomodulierende Oligopeptide |
DK2023952T3 (en) | 2006-05-18 | 2015-10-19 | Epimmune Inc | Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions |
US8282938B2 (en) * | 2008-11-28 | 2012-10-09 | National Institute Of Infectious Diseases | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain |
JP5792630B2 (ja) * | 2009-01-28 | 2015-10-14 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
ES2788863T3 (es) * | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
WO2015130488A2 (en) | 2014-02-28 | 2015-09-03 | Immunotope, Inc. | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
IL302345A (en) * | 2016-10-07 | 2023-06-01 | Enterome S A | Immunogenic compounds for cancer treatment |
US11712465B2 (en) | 2016-10-07 | 2023-08-01 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
CN117801069A (zh) | 2016-10-07 | 2024-04-02 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
US11111277B2 (en) | 2016-12-28 | 2021-09-07 | Invvax, Inc. | Influenza vaccines |
EP3574116A1 (de) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids |
NL2019814B1 (en) * | 2017-10-26 | 2019-05-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Methods for producing a MHC multimer. |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1995003777A1 (en) * | 1993-08-02 | 1995-02-09 | The Scripps Research Institute | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1012238A4 (de) * | 1997-01-31 | 2003-03-05 | Epimmune Inc | Peptide und mit peptiden beladene, antigen präsentierende zellen für die aktivierung von cytotoxischen t-zellen |
CA2400215A1 (en) * | 2000-02-23 | 2001-08-30 | Epimmune Inc. | Hla binding peptides and their uses |
-
2000
- 2000-06-28 WO PCT/US2000/017842 patent/WO2001000225A1/en active Application Filing
- 2000-06-28 EP EP00944976A patent/EP1189624A4/de not_active Withdrawn
- 2000-06-28 JP JP2001505934A patent/JP2003535024A/ja active Pending
- 2000-06-28 EP EP07117445A patent/EP1917970B1/de not_active Expired - Lifetime
- 2000-06-28 AU AU58984/00A patent/AU5898400A/en not_active Abandoned
- 2000-06-28 CA CA002370413A patent/CA2370413A1/en not_active Abandoned
- 2000-06-28 AT AT07117445T patent/ATE512666T1/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1995003777A1 (en) * | 1993-08-02 | 1995-02-09 | The Scripps Research Institute | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
Non-Patent Citations (1)
Title |
---|
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 685 - 693, XP002055570, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
EP1189624A1 (de) | 2002-03-27 |
WO2001000225A1 (en) | 2001-01-04 |
AU5898400A (en) | 2001-01-31 |
EP1917970A2 (de) | 2008-05-07 |
JP2003535024A (ja) | 2003-11-25 |
ATE512666T1 (de) | 2011-07-15 |
EP1917970B1 (de) | 2011-06-15 |
CA2370413A1 (en) | 2001-01-04 |
EP1917970A3 (de) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1189624A4 (de) | Hla-bindende peptide und deren verwendung | |
AU2001298049A8 (en) | Hla class i and ii binding peptides and their uses | |
SG49008A1 (en) | Hla-a2.1 binding peptides and their uses | |
EP0907370A4 (de) | Hla-a2.1 bindende peptide und deren verwendung | |
SG52492A1 (en) | Hla binding peptides and their uses | |
GB9624456D0 (en) | Assay method | |
AU5963500A (en) | Peptides for vaccinating against human cmv | |
EP1089757A4 (de) | Hla-bindende peptide und ihre verwendungen. | |
AU2273701A (en) | Hla class i a2 tumor associated antigen peptides and vaccine compositions | |
BR0017136A (pt) | Peptìdeos de ligação ao hla e seus usos. | |
EP1320377A4 (de) | Hla-bindungspeptide und ihre anwendungszwecke | |
WO2004007528A3 (en) | Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange | |
MXPA03010527A (es) | Composicion de vacuna. | |
WO1999047102A3 (en) | Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby | |
EP1605039A4 (de) | Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen | |
AU2062601A (en) | Peptides that stabilize protein antigens and enhance presentation to CD8+ T cells | |
WO2000071573A3 (en) | Immunogenic peptides derived from mage and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050111 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071220 |